Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Senhwa Biosciences, Inc. (6492.TWO)
New Taipei City, TW
Senhwa Biosciences, Inc., a pharmaceutical company established in 2012 and headquartered in New Taipei City, Taiwan, specializes in advancing novel drugs and targeted therapeutic agents. The firm is actively progressing several clinical programs. Its compound CX-5461 is undergoing various investigations, including a Phase I, open-label study assessing dose escalation, safety, pharmacokinetics, and pharmacodynamics of its intravenous administration in individuals with advanced blood cancers. CX-5461 is also in a Phase I trial for solid cancerous growths, as well as a Phase Ib expansion study focusing on solid tumors characterized by BRCA2 and/or PALB2 genetic mutations. Furthermore, CX-5461 is being evaluated in a Phase I trial alongside pidnarulex and talazoparib for patients battling metastatic castration-resistant prostate cancer. Beyond CX-5461, Senhwa is also developing several variations of CX-4945. CX-4945-CCA is participating in a Phase I/II clinical investigation, combined with gemcitabine, for treating cholangiocarcinoma. CX-4945-BCC is the subject of a Phase I, multi-center, open-label study, examining its safety and pharmacodynamic profile when administered orally twice daily to patients with advanced basal cell carcinoma. The company's CX-4945-MB compound is being explored in a Phase I/II and surgical study, led by a pediatric brain tumor consortium, for the management of recurrent SHH medulloblastoma. Lastly, CX-4945-AV06 is currently in a Phase II, double-blind, randomized, controlled study, designed to evaluate its safety and effectiveness in hospitalized adults afflicted with COVID-19.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.66% | -9.43% | -15.57% | -11.52% | +11.22% | +4.77% | +24.59% | -6.68% | -67.42% | -64.71% | -54.70% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+7.0% ★ Q1'26: -4.0% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+9.7% Q1'26: -8.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-24,104.4% Q1'26: -22,805.8% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-26,005.5% Q1'26: -28,722.1% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-2,463.3% Q1'26: -2,441.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%0.0% ★ Q1'26: +0.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.08× Q1'26: -0.08× (vs Q1'25)
| Metric |
Dec 2021 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
Dec 2031 1 Rev. Ana. 1 EPS Ana. |
Dec 2032 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
550.0K
est: 1.00M (-45.0%)
|
1.31M
1.31M – 1.31M
+30.8% YoY
|
1.95M
1.95M – 1.95M
+49.3% YoY
|
2.39M
2.39M – 2.39M
+22.2% YoY
|
1.00M
1.00M – 1.00M
-58.1% YoY
|
3.56M
3.56M – 3.56M
+256.4% YoY
|
4.36M
4.36M – 4.36M
+22.2% YoY
|
| EBITDA |
-321.59M
est: -1.00M (-32,058.7%)
|
-1.31M
-1.31M – -1.31M
-30.8% YoY
|
-1.95M
-1.95M – -1.95M
-49.3% YoY
|
-2.39M
-2.39M – -2.39M
-22.2% YoY
|
-1.00M
-1.00M – -1.00M
+58.1% YoY
|
-3.56M
-3.56M – -3.56M
-256.4% YoY
|
-4.36M
-4.36M – -4.36M
-22.2% YoY
|
| EBIT |
-327.82M
est: -1.00M (-32,682.1%)
|
-1.31M
-1.31M – -1.31M
-30.8% YoY
|
-1.95M
-1.95M – -1.95M
-49.3% YoY
|
-2.39M
-2.39M – -2.39M
-22.2% YoY
|
-1.00M
-1.00M – -1.00M
+58.1% YoY
|
-3.56M
-3.56M – -3.56M
-256.4% YoY
|
-4.36M
-4.36M – -4.36M
-22.2% YoY
|
| Net Income |
-329.26M
est: -336.18M (+2.1%)
|
-260.83M
-260.83M – -260.83M
+22.4% YoY
|
-473.68M
-473.68M – -473.68M
-81.6% YoY
|
-380.66M
-380.66M – -380.66M
+19.6% YoY
|
-336.03M
-336.03M – -336.03M
+11.7% YoY
|
-337.87M
-337.87M – -337.87M
-0.5% YoY
|
-327.17M
-327.17M – -327.17M
+3.2% YoY
|
| SGA |
64.94M
est: 79.17M (-18.0%)
|
83.21M
83.21M – 83.21M
+5.1% YoY
|
124.26M
124.26M – 124.26M
+49.3% YoY
|
151.86M
151.86M – 151.86M
+22.2% YoY
|
63.64M
63.64M – 63.64M
-58.1% YoY
|
226.78M
226.78M – 226.78M
+256.4% YoY
|
277.14M
277.14M – 277.14M
+22.2% YoY
|
| EPS |
-3.67
est: -3.77 (+2.6%)
|
-2.93
-2.93 – -2.93
+22.4% YoY
|
-5.31
-5.31 – -5.31
-81.6% YoY
|
-4.27
-4.27 – -4.27
+19.6% YoY
|
-3.77
-3.77 – -3.77
+11.7% YoY
|
-3.79
-3.79 – -3.79
-0.5% YoY
|
-3.67
-3.67 – -3.67
+3.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Sarah Chang | Executive Vice President, Chief Financial Officer & Accounting Supervisor | 9M | female |
| Jason Huang | Acting Chief Executive Officer & Chief Medical Officer | — | male |
| Joanne Lo | Acting Chief Operating Officer & Business Development Director | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 6492.TWO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
